Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies

Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocam...

Full description

Saved in:
Bibliographic Details
Published inScience Vol. 385; no. 6711; p. eabm6131
Main Authors Minhas, Paras S., Jones, Jeffrey R., Latif-Hernandez, Amira, Sugiura, Yuki, Durairaj, Aarooran S., Wang, Qian, Mhatre, Siddhita D., Uenaka, Takeshi, Crapser, Joshua, Conley, Travis, Ennerfelt, Hannah, Jung, Yoo Jin, Liu, Ling, Prasad, Praveena, Jenkins, Brenita C., Ay, Yeonglong Albert, Matrongolo, Matthew, Goodman, Ryan, Newmeyer, Traci, Heard, Kelly, Kang, Austin, Wilson, Edward N., Yang, Tao, Ullian, Erik M., Serrano, Geidy E., Beach, Thomas G., Wernig, Marius, Rabinowitz, Joshua D., Suematsu, Makoto, Longo, Frank M., McReynolds, Melanie R., Gage, Fred H., Andreasson, Katrin I.
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science (AAAS) 23.08.2024
The American Association for the Advancement of Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. Activation of astrocytic IDO1 by amyloid β and tau oligomers increases KYN and suppresses glycolysis in an aryl hydrocarbon receptor–dependent manner. In amyloid and tau models, IDO1 inhibition improves hippocampal glucose metabolism and rescues hippocampal long-term potentiation in a monocarboxylate transporter–dependent manner. In astrocytic and neuronal cocultures from AD subjects, IDO1 inhibition improved astrocytic production of lactate and uptake by neurons. Thus, IDO1 inhibitors presently developed for cancer might be repurposed for treatment of AD. Alzheimer’s disease has been associated with brain metabolic alterations. Minhas et al . studied the role of glucose metabolism impairments on disease progression using a combination of human induced pluripotent stem cells and mouse models (see the Perspective by Johnson and Macauley). The authors showed that activation of indoleamine-2,3-dioxygenase 1 (IDO1) by either amyloid β or tau oligomers, two prominent Alzheimer’s disease pathological proteins, promotes the conversion of tryptophan to kynurenine, which then suppresses astrocytic glycolysis, thus reducing one of the main fuel sources for neurons. Inhibiting IDO1 rescued synaptic plasticity in vitro and improved cognition in multiple rodent models. Targeting metabolic dysfunctions holds promise for the treatment of neurodegenerative disorders. —Mattia Maroso
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0036-8075
1095-9203
1095-9203
DOI:10.1126/science.abm6131